Advertisement

Journal of Gastroenterology

, Volume 46, Issue 4, pp 556–564 | Cite as

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

  • Akihiro TamoriEmail author
  • Tatsuya Koike
  • Hitoshi Goto
  • Shigeyuki Wakitani
  • Masahiro Tada
  • Hiroyasu Morikawa
  • Masaru Enomoto
  • Masaaki Inaba
  • Tatsuya Nakatani
  • Masayuki Hino
  • Norifumi Kawada
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Screening and prophylactic treatment for hepatitis B virus (HBV) reactivation is recommended for patients who receive immunosuppressive or cytotoxic therapy. The aim of this study was to clarify the prevalence of HBV reactivation in rheumatoid arthritis (RA) patients who had received more than 1 year of immunosuppressive therapy. This study also evaluated guidelines for determining HBV reactivation in patients with RA.

Methods

This was a prospective non-randomized, non-controlled study. We enrolled 50 patients with RA who had antibodies against hepatitis B core antigen (anti-HBc) and who had started treatment with disease-modifying anti-rheumatic drugs, including those who had additionally received anti-tumor necrosis factor-α (anti-TNF-α). HBV DNA levels were measured every 2–3 months by a real-time, polymerase chain reaction-based method. Entecavir was administered to patients with HBV DNA levels >2.1 log/ml.

Results

The mean observation period was 23 months (range 12–32 months). HBV reactivation occurred in 2 of 5 patients with HBV surface antigen (HBsAg) and in 1 of 45 patients without HBsAg. In patients who received anti-TNF-α therapy, antibodies against HBsAg decreased significantly. Entecavir therapy inhibited HBV amplification and prevented HBV-associated flares of hepatitis.

Conclusions

The incidence of HBV reactivation was low in RA patients in whom HBV infection had been resolved. Screening for HBV reactivation and prophylactic therapy with entecavir were effective means of preventing HBV-associated hepatic failure in patients with HBsAg, as well as in those with only anti-HBc who received immunosuppressive therapy for RA.

Keywords

Anti-tumor necrosis factor-α Anti-HBs Entecavir HBV reactivation Rheumatoid arthritis 

Abbreviations

ALT

Alanine aminotransferase

Anti-HBc

Antibodies against hepatitis B core antigen

Anti-HBs

Antibodies against HBsAg

Anti-TNF-α

Anti-tumor necrosis factor-α

DMARDs

Disease-modifying anti-rheumatic drugs

HBV

Hepatitis B virus

HBsAg

HBV surface antigen

MTX

Methotrexate

RA

Rheumatoid arthritis

Notes

Acknowledgments

We thank Ms. Rie Yasuda and Ms. Sanae Deguchi for their assistance in data/sample collection. This work was supported by the Liver Disease Research Fund in Osaka City University Graduate School of Medicine.

Conflict of interest

All authors declare that we have no conflict of interest in relation to the submission of this manuscript.

References

  1. 1.
    Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29:100–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006;4:1076–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.PubMedCrossRefGoogle Scholar
  7. 7.
    Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int. 2010. doi: 10.1007/s00296-009-1344-2.
  12. 12.
    Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:494–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2009. doi: 10.1007/s00296-009-1202-2.
  14. 14.
    Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–6.PubMedGoogle Scholar
  16. 16.
    Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888–9.PubMedGoogle Scholar
  17. 17.
    Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford). 2007;46:1381.CrossRefGoogle Scholar
  18. 18.
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al. British Society for Rheumatology; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009;48:436–9.CrossRefGoogle Scholar
  20. 20.
    Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;17:9–52.Google Scholar
  21. 21.
    Hyrich KL, Deighton C, Watson KD, Urkaregi A, Calabozo M, Quintana A. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 2009;48:1323–7.CrossRefGoogle Scholar
  22. 22.
    Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.PubMedCrossRefGoogle Scholar
  23. 23.
    Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, et al. Erratum to: The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting (J Clin Virol. 2008;41(4):243–54). J Clin Virol. 2008;42:104–15.Google Scholar
  24. 24.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Tsubouchi H, Kumada H, Kiyosawa K, Mochida S, Sakaida I, Tanaka E, et al. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Kanzo. 2009;50:38–42.CrossRefGoogle Scholar
  26. 26.
    Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.PubMedGoogle Scholar
  27. 27.
    Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2010. doi: 10.1007/s10165-010-0337-z.
  29. 29.
    Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol. 2007;45:828–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Usuda S, Okamoto H, Tanaka T, Kidd-Ljunggren K, Holland PV, Miyakawa Y, et al. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J Virol Methods. 2000;87:81–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527–32.PubMedCrossRefGoogle Scholar
  35. 35.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.PubMedGoogle Scholar
  36. 36.
    Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med. 1987;316:965–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003;77:2469–76.PubMedCrossRefGoogle Scholar
  40. 40.
    Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, Janssen HL, et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology. 2007;46:699–705.PubMedCrossRefGoogle Scholar
  41. 41.
    Velu V, Saravanan S, Nandakumar S, Shankar EM, Vengatesan A, Jadhav SS, et al. Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J Gastroenterol. 2008;14:3534–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Akihiro Tamori
    • 1
    Email author
  • Tatsuya Koike
    • 2
  • Hitoshi Goto
    • 3
  • Shigeyuki Wakitani
    • 4
  • Masahiro Tada
    • 4
  • Hiroyasu Morikawa
    • 1
  • Masaru Enomoto
    • 1
  • Masaaki Inaba
    • 3
  • Tatsuya Nakatani
    • 5
  • Masayuki Hino
    • 6
  • Norifumi Kawada
    • 1
  1. 1.Department of HepatologyOsaka City University Graduate School of MedicineOsakaJapan
  2. 2.Department of RheumatosurgeryOsaka City University Graduate School of MedicineOsakaJapan
  3. 3.Department of Metabolism, Endocrinology and Molecular MedicineOsaka City University Graduate School of MedicineOsakaJapan
  4. 4.Department of Orthopaedic SurgeryOsaka City University Graduate School of MedicineOsakaJapan
  5. 5.Department of UrologyOsaka City University Graduate School of MedicineOsakaJapan
  6. 6.Department of HematologyOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations